{
    "nct_id": "NCT05933577",
    "official_title": "A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma (INTerpath-001)",
    "inclusion_criteria": "The main inclusion criteria include but are not limited to the following:\n\n* Has surgically resected and histologically/pathologically confirmed diagnosis of Stage IIB or IIC, III, or IV cutaneous melanoma\n* Has not received any prior systemic therapy for their melanoma beyond surgical resection\n* No more than 13 weeks have passed between final surgical resection that rendered the participant disease-free and the first dose of pembrolizumab\n* Is disease free at the time of providing documented consent for the study\n* Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on anti-retroviral therapy (ART)\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "The main exclusion criteria include but are not limited to the following:\n\n* Has ocular or mucosal melanoma\n* Has cancer that has spread to other parts of the body and cannot be removed with surgery\n* Has heart failure within the past 6 months\n* Has received prior cancer therapy or another cancer vaccine\n* Has another known cancer that that has spread to other parts of the body or has required treatment within the past 3 years\n* Has severe reaction to study medications or any of their substance used to prepare a drug\n* Have not recovered from major surgery or have ongoing surgical complications",
    "miscellaneous_criteria": ""
}